Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Warmed Saline for Vaso-Oclusive Episodes in Sickle Cell Disease
source: The American Academy of Pediatrics
year: 2020
summary/abstract:Investigators from the University of Maryland Medical Center, Baltimore, and Nationwide Children’s Hospital, Columbus, OH, conducted a randomized controlled trial to assess the effectiveness of warmed IV saline administered to children with vaso-occlusive episodes (VOE) and sickle cell disease (SCD). Children 4–21 years with known SCD who required treatment for uncomplicated VOE at Nationwide Children’s Hospital between November 2012 and June 2014 were eligible. VOE was defined as pain in the back, extremities, abdomen, or chest rated as >3 on the Wong-Baker FACES scale. Study patients were randomized to receive either IV saline warmed to 37.5°C (intervention) or at room temperature (22°C–24°C control). Children in both groups received a 20 ml/kg bolus of IV saline, then provided fluid at a maintenance rate.
DOI: 10.1542/gr.44-3-35read more
+myBinderRelated Content
-
Discovery First in Human: Bringing Awareness of Sickle Cell Diseasehttps://www.youtube.com/watch?v=kffu_YvJ...
-
Sancilio Pharmaceuticals Company, Inc. (SPCI) Receives Rare Pediatric Disease Designation From the US Food and Drug ...Sancilio Pharmaceuticals Company, Inc. (...
-
Sickle Cell DiseaseSickle cell disease, a rare hematologica...
-
Phase 1 trial to test under-the-skin injection of sevuparin in sickle cell patientsModus Therapeutics is going to launch ...
-
Lab-Grown Blood: What Is It, and How Could It Be Useful?Sometimes a person may have a blood diso...
-
Use of telemedicine to improve access to clinical services and treatment for children with sickle cell diseasePatients with sickle cell disease (SCD) ...
-
GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)Global Blood Therapeutics, Inc. (GBT) to...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.